pmc 6 biogenix

Primary Amides

PRODUCT SPECIFICATION

Kemamide[®] OR

Product Description

Kemamide[®] **OR** is an unsaturated fatty primary monoamide derived from oleic acid. This product is available in bead or powder form.

Applications

Most uses of Kemamide[®] OR fatty amide are based on its slip properties. It can be used as a slip agent in polyethylene and polyolefin films; as a release and antistatic agent in molding and forming plastic; as a dyestuff dispersant for printing inks and surface coatings; as a cosmetic additive; and as a blending agent for paraffin waxes and polyamide resins, and as a component of lubricant and grease formulations.

Product Specifications

Test	Specification
Acid Number	0.00 - 1.00
Amide %	98.0 - 100.0
Gardner Color (1963)	0.0 - 2.0
Iodine Value	72.0 - 95.0
Closed Tube Melt Point	70.0 - 78.0
Water %	0.00 - 0.20

Solubility

Kemamide[®] OR fatty amide is relatively insoluble in water. In oxygenated organic solvents at ambient temperatures, it is soluble to levels of up to 10% by weight.

PMC Biogenix, Inc 1231 Pope Street Memphis, TN 38028

Customer Service Phone: 800-641-2152 Fax: 800-641-2153

Page 1 of 3

The information contained herein is correct to the best of our knowledge. Your attention is directed to the pertinent Material Safety Data Sheets for the products mentioned herein. All sales are subject to PMC Biogenix, Inc's standard terms and conditions of sale, copies of which are available upon request and which are part of PMC Biogenix, Inc's invoices and/or order acknowledgements. Except as expressly provided in PMC Biogenix, Inc's standard terms and conditions of sale, no warranty, expressed or implied, including warranties of merchantability or fitness for a particular purpose, is made with respect to the products described herein. Nothing contained herein shall constitute permission or recommendation to practice any invention covered by a patent without a license from the owner of the patent.

Kemamide[®] OR

FDA Status

Kemamide[®] **OR** fatty amide is sanctioned by the U.S. Food and Drug Administration (FDA) under Title 21 of the *Code of Federal Regulations* (21 CFR) as indicated in the following sections:

In adhesives	175.105
In can end cements (resinous and polymeric coatings)	175.300
For use in xylene-formaldehyde resins condensed with 4,4'- isopropylidenediphenol-epichlorhydrin epoxy resins	175.380
In zinc-silicon dioxide matrix coatings	175.390
As a component of paper and paperboard in contact with aqueous and fatty foods	176.170
In closures with sealing gaskets for food containers	177.1210
In ethylene-vinyl acetate copolymers	177.1350
For use in surface lubricants used in manufacturing metallic articles	178.3910
In packaging materials for use in the radiation preservation of prepackaged food	179.45
For use as a release agent in manufacturing food packaging materials	181.28

This FDA status information is intended to provide an overview only and is not intended to be an alternative to reading the FDA regulations. The above CFR sections should always be consulted for the complete context before any conclusion is made as to the allowed regulated use.

PMC Biogenix, Inc 1231 Pope Street Memphis, TN 38028

Customer Service Phone: 800-641-2152 Fax: 800-641-2153

Page 2 of 3

The information contained herein is correct to the best of our knowledge. Your attention is directed to the pertinent Material Safety Data Sheets for the products mentioned herein. All sales are subject to PMC Biogenix, Inc's standard terms and conditions of sale, copies of which are available upon request and which are part of PMC Biogenix, Inc's invoices and/or order acknowledgements. Except as expressly provided in PMC Biogenix, Inc's standard terms and conditions of sale, no warranty, expressed or implied, including warranties of merchantability or fitness for a particular purpose, is made with respect to the products described herein. Nothing contained herein shall constitute permission or recommendation to practice any invention covered by a patent without a license from the owner of the patent.

PRODUCT SPECIFICATION

Kemamide[®] OR

Safety and Handling

The Kemamide[®] fatty amide compounds are not primary skin irritants by the Draize Test (Federal Hazardous Substances Act). Avoid contact with skin and eyes.

In case of accidental eye contact, flush with large amounts of water and call a physician. If swallowed, call a physician.

The Kemamide[®] fatty amide compounds are not regulated by the Department of Transportation (DOT). They are not corrosive and not flammable by DOT definitions. However, if these products are supplied in powder form, in-process dusting should be minimized, otherwise an explosive hazard could develop. Avoid all sources of ignition when handling this product.

The Kemamide[®] fatty amide compounds, although chemically stable, should be kept away from strong oxidizing agents. Holding the Kemamide[®] products in a molten state or exposure to high temperatures should be minimized to retain product quality.

Please consult the Material Safety Data Sheet for additional information on safety, handling and storage before using this product.

June 2008 © 2008 PMC Biogenix, Inc.

PMC Biogenix, Inc 1231 Pope Street Memphis, TN 38028

Customer Service Phone: 800-641-2152 Fax: 800-641-2153

Page 3 of 3

The information contained herein is correct to the best of our knowledge. Your attention is directed to the pertinent Material Safety Data Sheets for the products mentioned herein. All sales are subject to PMC Biogenix, Inc's standard terms and conditions of sale, copies of which are available upon request and which are part of PMC Biogenix, Inc's invoices and/or order acknowledgements. Except as expressly provided in PMC Biogenix, Inc's standard terms and conditions of sale, no warranty, expressed or implied, including warranties of merchantability or fitness for a particular purpose, is made with respect to the products described herein. Nothing contained herein shall constitute permission or recommendation to practice any invention covered by a patent without a license from the owner of the patent.